Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.320 -0.040 (-0.92%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 2, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	17,620,930
Open	4.370
Bid (Size)	4.350 (100)
Ask (Size)	4.360 (400)
Prev. Close	4.360
Today's Range	4.310 - 4.517
52wk Range	3.790 - 12.36
Shares Outstanding	168,425,907
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture

December 01, 2025

Artificial intelligence, often spotlighted for its advancements in mainstream applications like conversational agents and autonomous vehicles, is quietly orchestrating a profound transformation across...

Via TokenRing AI

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

December 01, 2025

From Recursion Pharmaceuticals

Via GlobeNewswire

Performance

YTD	-40.1%	-40.1%
1 Month	-20.6%	-20.6%
3 Month	-7.3%	-7.3%
6 Month	-1.6%	-1.6%
1 Year	-43.0%	-43.0%

More News

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

popEVE AI: Harvard-Developed Model Set to Revolutionize Rare Disease Diagnosis and Drug Discovery

November 25, 2025

Via TokenRing AI

Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? ↗

November 24, 2025

Via The Motley Fool

Is Recursion Pharmaceuticals a Meme Stock? ↗

November 19, 2025

Via The Motley Fool

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

November 18, 2025

Via FinancialNewsMedia

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

November 18, 2025

From MarketNewsUpdates.com

Via GlobeNewswire

Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025

November 14, 2025

Via MarketMinute

Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock ↗

November 12, 2025

Via The Motley Fool

AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures

November 06, 2025

Via TokenRing AI

Nvidia's AI Reign: A $5 Trillion Bellwether Shaping Wall Street's Fortunes

November 11, 2025

Via MarketMinute

Recursion Pharmaceuticals (NASDAQ:RXRX) Reports Q3 2025 Results with Revenue Miss and Extended Cash Runway ↗

November 05, 2025

Via Chartmill

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

November 05, 2025

From Recursion Pharmaceuticals

Via GlobeNewswire

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

November 05, 2025

From Recursion Pharmaceuticals

Via GlobeNewswire

AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential

November 04, 2025

Via TokenRing AI

3 Things Investors Need to Know About Recursion Pharmaceuticals ↗

November 04, 2025

Via The Motley Fool

Recursion to Participate in Upcoming Investor Conferences

November 04, 2025

From Recursion Pharmaceuticals

Via GlobeNewswire

The AI Imperative: Why Rapid Upskilling is Non-Negotiable for Pharma’s Future

October 31, 2025

Via TokenRing AI

AI Revolutionizes Pharma R&D: A New Era of Accelerated Drug Discovery and Personalized Medicine

October 31, 2025

Via TokenRing AI

Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? ↗

October 31, 2025

Via The Motley Fool

AI Revolutionizes Drug Discovery and Personalized Medicine: A New Era of Healthcare

October 22, 2025

Via TokenRing AI

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

October 28, 2025

From Recursion Pharmaceuticals

Via GlobeNewswire

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks ↗

October 22, 2025

Via Benzinga

Short Squeeze Frenzy Fuels October's Market Rebound: A Closer Look at Bearish Bets and Bullish Surges

October 21, 2025

Via MarketMinute

Frequently Asked Questions

Is Recursion Pharmaceuticals, Inc. - Class A Common Stock publicly traded?

Yes, Recursion Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.

What exchange does Recursion Pharmaceuticals, Inc. - Class A Common Stock trade on?

Recursion Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock?

The ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock is RXRX on the Nasdaq Stock Market

What is the current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock?

The current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 4.320

When was Recursion Pharmaceuticals, Inc. - Class A Common Stock last traded?

The last trade of Recursion Pharmaceuticals, Inc. - Class A Common Stock was at 12/02/25 04:00 PM ET

What is the market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock?

The market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 727.60M

How many shares of Recursion Pharmaceuticals, Inc. - Class A Common Stock are outstanding?

Recursion Pharmaceuticals, Inc. - Class A Common Stock has 728M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.